Dr. Suzanne Shusterman, MD
Pediatric Hematology & Oncology (Pediatric Hematology & Oncology Physician)
44 Binney St, Room G350, Dana Farber Cancer Institute
Boston, MA 02115
At a glance
- Medical school
- University of Massachusetts Medical School (1993)
- Years since graduation
- 33
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1993Medical school: University of Massachusetts Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Hematology & Oncology Physician primary
MA license 222794
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Children's Hospital Pediatric Associates, Inc (328 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $4,117 in research payments for these studies, mostly to the institutions running them.
- A phase 12 study to evaluate the safety and pharmacokinetics of bosutinib in pediatric patients with cml who are resistant or intolerant to at least one prior tyrosine kinase inhibitor therapy
Pfizer Inc. - A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearranged and or JAK Pathway Mutant Acute Lymphoblastic Leukemia
Incyte Corporation - Open Label Dose Escalation and Expansion Study of Entrectinib RXDX 101 in Children
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.